Search

Immune cells called neutrophils are the first responders to sites of infection. A new study probes what gets them there.

… Tuesday, May 15, 2018 VIDEO | 00:04 Neutrophil Recruitment — What's Damage Got to Do with It? Video Details Wounding a zebrafish tail fin triggers a wave of calcium (the blue here is a low calcium area; the red, high calcium) that signals damage and recruits neutrophils. Summary Scientists at the Sloan

A drug already approved for anemia offers hope for people with acute myeloid leukemia.

… Monday, March 25, 2019 Summary Leukemia Leukemia cells have an impaired ability to get rid of iron. A nanoparticle drug called ferumoxytol delivers additional iron to these cells. The excess iron causes the leukemia cells to die. Ferumoxytol is already approved to treat anemia, so researchers know the

The July 22 MSK Science Spotlight features Luis Diaz, MD, Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.”

… Wednesday, July 22, 2020 The July 22 MSK Science Spotlight features Luis Diaz, MD , Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.” An accomplished physician, pioneering researcher, and leader in the field

You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.

… Wednesday, March 8, 2023 You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also

Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells.

… Monday, October 8, 2012 Summary Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells. For the first time, a team of Memorial Sloan Kettering investigators has synthesized erythropoietin (also known as EPO), the hormone

Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the Northeast, the number two cancer hospital in the nation, and the number one hospital for urology care by U.S. News & World Report in its annual Best Hospitals list. MSK has held its position as a top-two cancer hospital in the U.S. and the best cancer center in the Northeast since these rankings were established 35 years ago.

… Tuesday, July 16, 2024 Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the Northeast, the number two cancer hospital in the nation, and the number one hospital for urology care by U.S. News & World Report in its annual Best Hospitals list. MSK has held its

MSK researchers have led much of the research looking at how people with blood cancers respond to COVID-19 infections and vaccines.

… Tuesday, December 21, 2021 Doctors and scientists at Memorial Sloan Kettering Cancer Center have played a leading role in understanding how COVID-19 affects people with cancer. MSK investigators have published a number of pioneering studies on the topic, which have contributed to the care of patients

… Wednesday, August 3, 2022 First, the good news: There’s no evidence that tattoos cause skin cancer , says Memorial Sloan Kettering Cancer Center (MSK) dermatologist Jennifer DeFazio , who cares for people at the MSK Skin Cancer Center Hauppauge . A dermatologist is a doctor who specializes in skin, hair

New MSK research combined sophisticated genetically engineered mouse models and advanced computational methods to map the earliest cell states leading to pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.

… Thursday, May 11, 2023 Discussions of cancer often stress the genetic mutations that drive disease by altering the normal function of cellular proteins. KRAS , for example, normally acts as an on/off switch for cellular proliferation, but mutations to the gene — common in lung cancer, colorectal cancer

Ingo Mellinghoff is optimistic about the future of brain cancer treatments as the new Chair of MSK’s Department of Neurology.

… Thursday, March 11, 2021 Summary Neuro-oncologist Ingo Mellinghoff first became intrigued by scientific questions regarding brain tumors while working in the lab of physician-scientist Charles Sawyers before both came to MSK. Now, Dr. Mellinghoff leads MSK’s Department of Neurology as it deploys innovative